8 / 8
Page 40
Notes:
conferenceseries
.com
Volume 5
Toxicology: Open Access
Toxicology Congress 2019
May 06-07, 2019
May 06-07, 2019 Tokyo, Japan
20
th
World Congress on
Toxicology and Pharmacology
Toxicol Open Access 2019, Volume 5
DOI: 10.4172/2476-2067-C1-009
Therapeutics effect of Idebenone in murine colitis
Sonia Shastri
University of Tasmania, Australia
I
debenone short chain quinone has been described as a potent antioxidant and mitochondrial electron donor. Its therapeutical
potentialhasbeendescribedextensivelyinnumerouspathologicalconditionsrangingfromneurodegenerative,neuromuscular
to diverse metabolic conditions. There is also some emerging evidence that Idebenone has some anti-inflammatory activity.
Oxidative stress is one of the key players of the inflammatory cascade responsible for the initiation of Ulcerative Colitis (UC).
Therefore, we investigated the anti-oxidative and anti-inflammatory properties of Idebenone in Dextran Sodium Sulfate (DSS)
induced mouse model of acute colitis. Acute colitis was introduced in female C57BL/6J mice by administering 2.5% of DSS
in autoclaved water continuously for seven days. Changes in body weight, Disease Activity Index (DAI), colon length and
histopathological parameters were evaluated and scored. Colonic contents of Malondialdehyde (MDA), a marker of lipid
peroxidation were also examined as a parameter of disease-associated redox state. Protein expression of the oxidative stress
induced redox factor NAD(P)H dehydrogenase Quinone-1 (NQO-1) was determined by western blot, while the levels of
various pro-inflammatory cytokines were quantified using Bio-Plex assay. On Oral administration of Idebenone at a dose of
200 mg/kg body weight significantly against body weight loss and improved DAI, colon length and histopathology. Idebenone
also significantly reduced MDA content as well as pro-inflammatory cytokine levels such as IL-1α, TNF-α, G-CSF, GM-CSF,
MIP-1α, MIP-1β, RANTES and EOTAXIN and furthermore, Idebenone upregulated NQO1 protein levels. These results
suggest that Idebenone could represent a promising therapeutic strategy to interfere with disease pathology in UC by inducing
anti-oxidative and anti-inflammatory pathways.
Sonia.shastri@utas.edu.au